Subject:
- Active Substance: Migalastat
- Name: Galafold®
- Therapeutic area: Fabry disease
- Pharmaceutical company: Amicus Therapeutics GmbH
Time table:
- Start: 01.09.2021
- Final decision by G-BA: 17.02.2022
Final decision:
- Hint for a non-quantifiable additional benefit (orphan drug)